CentralSouthPharmacy.July2011,Vol 9No 7 中南药学2011年7月第9卷第7期[6]
RizzoM,RiniGB,BerneisK.Effectsofstatins,fibrates,rosu-vastatinandezetimibebeyondcholesterol:themodulationofLDLsizeandsubclassesinhigh-riskpatients[J].AdvTher,2007,24(3):575-582.[7]
vanBilsenM,vanNieuwenhovenFA.PPARsastherapeutictargetsincardiovasculardisease[J].ExpertOpinTherTar-gets,2010,14(10):1029-1045.[8]
UndasA,Celi iska-L wenhoffM.Antiplateleteffectsofm-icronizedfenofibrateinsubjectswithdyslipidemia[J].PolArchMedWewn,2007,117(5-6):235-240.[9]
JeanpierreE,LeTourneauT,ZawadzkiC,etal.Beneficialeffectsoffenofibrateonplaquethrombogenicityandplaquesta-bilityinatheroscleroticrabbits[J].CardiovascPathol,2009,18(3):140-147.[10]
TenenbaumA,FismanEZ,BoykoV,etal.Attenuationofprogressionofinsulinresistanceinpatientswithcoronaryar-terydiseasebybezafibrate[J].ArchInternMed,2006,166(7):737-741.
[11]
FrickMH,EloO,HaapaK,etal.HelsinkiHeartStudy:primarypreventiontrialwithgemfibrozilinmiddle-agedmenwithdyslipidemia.Safetyoftreatment,changesinriskfac-tors,andincidenceofcoronaryheartdisease[J].NEnglJMed,1987,317(20):1237-1245.[12]
Effectoffenofibrateonprogressionofcoronary-arterydiseaseintype2diabetes:theDiabetesAtherosclerosisInterventionStudy,arandomisedstudy[J].Lancet,2001,357(9260):905-910.[13]
RubinsH,DavenportJ,VA-HITStudyGroup,etal.Reduc-tioninstrokewithgemfibrozilinmenwithcoronaryheartdis-easeandlowHDLcholesterol:TheVeteransAffairsHDLIn-terventionTrial(VA-HIT)(23):2828-2833.[14]
GoldenbergI,GoldbourtU,BoykoV,etal.Relationbe-tweenon-treatmentincrementsinserumhigh-densitylipopro-teincholesterollevelsandcardiacmortalityinpatientswithcoronaryheartdisease(fromtheBezafibrateInfarctionPreven-tiontrial)[J].AmJCardiol,2006,97(4):466-471.[15]
TenenbaumA,MotroM,FismanEZ,etal.Bezafibrateforthesecondarypreventionofmyocardialinfarctioninpatientswiththemetabolicsyndrome[J].ArchInternMed,2005,165(10):1154-1160.[16]
BurgessDC,HuntD,LiL,etal.Incidenceandpredictorsofsilentmyocardialinfarctionintype2diabetesandtheeffectoffenofibrate:ananalysisfromtheFenofibrateInterventionandEventLoweringinDiabetes(FIELD)study[J].EurHeartJ,2010,31(1):92-99.[17]
RobinsSJ,BloomfieldHE.Fibricacidderivativesincardiovas-culardiseaseprevention:resultsfromthelargeclinicaltrials[J].CurrOpinLipidol,2006,17(4):431-439.[18]
中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-[31][30][29][28][27]
[J].Circulation,2001,103
[26][25][24][23][22][21][20][19]
409.
PauciulloP,BorgninoC,PaolettiR,etal.Efficacyandsafetyofacombinationoffluvastatinandbezafibrateinpatientswithmixedhyperlipidaemia(FACTstudy)[J].Atherosclerosis,2000,150(2):429-436.
GrundySM,VegaGL,YuanZ,etal.Effectivenessandtoler-abilityofsimvastatinplusfenofibrateforcombinedhyperlip-idemia(theSAFARItrial)[J].AmJCardiol,2005,95(4):462-468.
胡大一,马长生.心脏病学实践2010[M].北京:人民卫生出版社,2010:638-642.
ElamM,LovatoLC,GinsbergH.Roleoffibratesincardio-vasculardiseaseprevention,theACCORD-Lipidperspective.CurrOpinLipidol,2011,22(1):55-61.
Reyes-SofferG,Rondon-ClavoC,GinsbergHN.Combina-tiontherapywithstatinandfibrateinpatientswithdyslip-idemiaassociatedwithinsulinresistance,metabolicsyndromeandtype2diabetesmellitus[J].ExpertOpinPharmacother,2011,12(9):1429-1438.
W gnerAM,S nchez-QuesadaJL,Ben tezS,etal.Effectofstatinandfibratetreatmentoninflammationintype2diabetes.Arandomized,cross-overstudy[J].DiabetesResClinPract,2011,3,25.[Epubaheadofprint]doc.guandang.net.
CamerinoGM,PellegrinoMA,BroccaL,etal.Statinorf-ibratechronictreatmentmodifiestheproteomicprofileofratskeletalmuscle[J].1054-1064.
GoldbergAC,BittnerV,PepineCJ,etal.Efficacyoffenof-ibricacidplusstatinsonmultiplelipidparametersanditssafetyinwomenwithmixeddyslipidemia[J].AmJCardiol,2011,107(6):898-905.
EngerC,GatelyR,MingEE,etal.Pharmacoepidemiologysafetystudyoffibrateandstatinconcomitanttherapy[J].AmJCardiol,2010,106(11):1594-1601.
Fenofibrateprofiledasthefibratewithadditionalnewdata,supportingitsusewithstatinsintheEuropeanMedicinesA-gencyrecommendations[J].CardiovascJAfr,2011,22(1):55.
StaffaJA,ChangJ,GreenL.Cerivastatinandreportsoffatalrhabdomyolysis[J].NEnglJMed,2002,346(7):539-540.
MochalinVN,SagarA,GourS,etal.Manufacturingnanos-izedfenofibratebysaltassistedmilling[J].2009,26(6):1365-1370.
JuenemannD,JantratidE,WagnerC,etal.Biorelevantinvitrodissolutiontestingofproductscontainingmicronizedornanosizedfenofibratewithaviewtopredictingplasmaprofiles[J].EurJPharmBiopharm,2011,77(2):257-264.
(收稿日期:2011-04-29;修回日期:2011-05-18)
PharmRes,
BiochemPharmacol,201181(8):
542
Ju ly 2011, V ol 9 N o 7 高脂血症的药物治疗专题 贝特类调脂药物研究进展龚海荣, 李向平 * , 梁思宇 ( 中南大学湘雅二医院心血管内科, 长沙 410011) ...
贝特类调脂药物在降脂领域的地位及认识_专业资料。贝特类药物又称苯氧芳酸类药物。研究表明,贝特类药物除了具有调脂作用外.还具有抗炎、降低纤维蛋白原及部分凝血因...
贝特类药物的研究进展_医药卫生_专业资料。贝特类药物的研究进展 贝特类药物的前...贝特类药物的调脂作用 ? 贝特类药物通过激活PPARα ,刺激LPL(脂蛋白脂酶)、 ...
研究表明, 贝特类药物除了具有调脂作用外, 还具有抗炎、降低纤维蛋白原及部分凝血因子水平、改善胰岛素敏 感性、 改善内 皮细胞功能等调脂以外的抗动脉粥样 硬化...
研究表明, 贝特类药物除了具有调脂作用外 , 还具有抗炎、降 低纤维蛋白原及部分凝血因子水平、改善胰岛素敏 感性、改善内皮细胞功能等调脂以外的抗动脉粥样 硬化...
研究证实,贝特类 药物可能延缓冠状动脉粥样硬化 的进展,减少主要冠脉事件。贝 特类的这种抗动脉粥样硬化机 制,不仅与其调脂作用有关,还 在于其对非脂质危险因素的...
贝特类调脂药物治疗2型糖尿病患者调脂的作用_医药卫生_专业资料 暂无评价
· 210· 现代医药卫生 2014 年 1 月 30 日 第 30 卷第 2 期 J Mod Med Health ,January 30 ,2014 ,Vol.30 ,No.2 ·综述与讲座· 贝特类调脂药物...
其多数药物的译名中含有“贝特”二字, 如氯贝特、苯扎贝特、非诺贝特等,故常...贝特类药物的研究进展 暂无评价 16页 免费 贝特类调脂药物研究进展 4页 免费 ...
热门文档